Managing chronic hepatitis C in HIV-infected patients

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic hepatitis C has become a leading cause of morbidity and mortality among HIV-infected persons. All HIV-infected patients should be tested for chronic hepatitis C, and those who are being considered for treatment should undergo genotype assay and quantitative hepatitis C virus (HCV) RNA testing. The HCV genotype is an important predictor of response to therapy and can assist in the treatment decision; the quantitative HCV RNA level is most useful in monitoring response to therapy The introduction of pegylated interferon (PEG-IFN) alfa represents an important advance in the treatment of hepatitis C. PEG-IFN is administered weekly by subcutaneous injection; the recommended regimen also includes oral ribavirin, 800 to 1200 mg daily in 2 divided doses. Many specialists recommend treating all HCV-HIV-coinfected patients for a minimum of 48 weeks.

Original languageEnglish (US)
Pages (from-to)241-256
Number of pages16
JournalInfections in Medicine
Volume23
Issue number6
StatePublished - Jun 2006
Externally publishedYes

Keywords

  • AIDS
  • End-stage liver disease
  • Hepatitis C
  • Human immunodeficiency virus
  • Pegylated interferon alfa
  • Ribavirin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Managing chronic hepatitis C in HIV-infected patients'. Together they form a unique fingerprint.

Cite this